Molecular formula alone — C225H348N48O68 — says little about why tirzepatide behaves the way it does in a binding assay; that comes down to how its parts are arranged.
Backbone and modifications
Tirzepatide is a synthetic peptide of 39 amino-acid residues, built on a backbone derived from native GIP and modified at several positions with non-standard amino acids not encoded in the natural genetic code. Those substitutions do two things: they let the peptide additionally engage the GLP-1 receptor, and they increase the backbone's resistance to enzymatic breakdown compared with an unmodified natural peptide sequence. For comparison, native GIP and GLP-1 are considerably shorter, unmodified peptides without any lipid attachment, which is part of why they clear the body so quickly relative to engineered analogs like tirzepatide. The result is a single chain capable of activating two distinct incretin receptors, a property whose downstream pharmacology is a subject of its own within incretin research.
The fatty-diacid linker
Attached to the peptide backbone, via a linker to a lysine side chain, is a C20 fatty-diacid moiety. This lipid portion is the same general engineering strategy used in other long-acting peptides under study, including the acylation seen in semaglutide's structure: the fatty chain promotes reversible binding to serum albumin once the peptide is in circulation, which slows clearance from the bloodstream and extends the compound's measurable activity window in pharmacokinetic research. Without that modification, an unconjugated peptide of similar size would typically be cleared far more rapidly by renal filtration and peptidase activity.
Manufacturing and verification
Peptides of this size and complexity are generally produced by solid-phase peptide synthesis, in which amino acids are added one residue at a time to a resin-bound chain, followed by selective side-chain deprotection, conjugation of the fatty-diacid linker, cleavage from the resin, and purification by preparative chromatography. Because the finished molecule combines a long peptide chain with a bulky lipid conjugate, purification typically requires chromatographic conditions optimized differently from those used for smaller, unmodified peptides. Background on how amino-acid sequences are assembled and read is covered in understanding amino acid sequences in peptides, and confirmation of the finished molecule's mass and purity is discussed in HPLC vs. mass spectrometry. The finished molecule has a molecular weight of roughly 4813.5 daltons, reflecting the added mass of the fatty-diacid conjugate on top of the 39-residue backbone. Unlike some peptide hormone families, GIP- and GLP-1-derived peptides such as tirzepatide are linear chains without internal disulfide bridges, which simplifies certain aspects of both synthesis and downstream analytical characterization relative to disulfide-containing peptides.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.
See a third-party–tested compound: BPC-157 (batch COA available) →